Pharma News

AMAG Pharmaceuticals, Inc announced the issuance of U.S. Patent Number 9,844,558 entitled “Methods of Reducing Risk of Preterm Birth.” This newly issued patent is directed to subcutaneous administration and dosing of Makena® (hydroxyprogesterone caproate injection) and is expected to expire on May 2, 2036. Makena is a treatment to reduce the risk of preterm birth in women who are pregnant with one baby and who spontaneously delivered one preterm baby in the past.

Suven Life Sciences Ltd (Suven) granted of one product patent from Canada (2932428) and one product patent from India (289123) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2028 respectively.

Lincoln Pharmaceuticals Ltd. has been awarded a Patent for “An Arteether Injection For Treatment of Malaria”, Patent No.258915 by Government of India for Antimalarial Drug. In the present time, this formulation, “Arteether !njection”are available in market in 3ml and 2ml ampoules form. At the time of injecting “Arteether Injection” to the patient by doctors , it is very painful for a long time. Patient will have to take this injection at least for a period of three days to control the malaria.

F. Hoffmann-La Roche Ltd. obtained approval from the European Commission, for Alecensa® as monotherapy indicated for “the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)”. In addition, the EU marketing authorisation for Alecensa has been switched from conditional approval (given in February 2017) to a full approval for the treatment of people with ALK-positive, metastatic NSCLC who have progressed on or are intolerant to crizotinib (second-line).

Mentice boosts its US development presence and adds a clinical training service line with the acquisition of Medical Simulation Corporation's (MSC) Medical Products division. Mentice is the global leader of simulation-based performance solutions for endovascular therapies.

The Indian Pharmaceutical Association (IPA) Anantapuramu Local Branch, Head Quarters at Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu celebrated the National Pharmacy Week (NPW) 2017, in association with University College of Pharmaceutical Sciences - Sri Krishnadevaraya University and Oil Technological and Pharmaceutical Research Institute - [OTPRI], Anantapuramu, Andhra Pradesh.

The US subsidiary of Dr. Reddy’s Laboratories Ltd. announced that it has reached a settlement with the US Government, in a case that is more than six years old, involving packaging for five blister-packed prescription products. In a joint filing by the parties, Dr. Reddy’s and the US Department of Justice agreed to the settlement of the action without any adjudication of any issue of fact or law.

Teva Pharmaceutical Industries Ltd announced the exclusive launch of generic Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg in the U.S.

Aclaris Therapeutics, Inc a dermatologist-led biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number with age. The condition is more prevalent than acne, psoriasis and rosacea combined.